Skip to main content

Table 3 Distribution of outcomes and progression of diseases between both groups

From: The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis

Outcomes C3GN
(n = 10)
C3
(n = 21)
P value
Follow up (days) 405 (203–1197) 1822 (1243–3948) 0.02
Remission with immunosuppression (%) 20 (n = 2) 33(n = 7) 0.5
Partial remission with immunosuppression (%) 10 (n = 1) 10 (n = 2) 0.9
Remission without immunosuppression (%) Nil 19 (n = 4)  
Partial remission without immunosuppression (%) Nil Nil  
Relapse (%) nil 5 (n = 1) 0.5
Creatinine doubling (%) 10 (n = 1) 19 (n = 4) 0.2
Median Creatinine doubling time (days) 350 NA 1107.5 (522–2076) 0.3
Median Creatinine doubling amount (umol/L) 353** NA 245 (229–277) 0.3
Latest Creatinine (umol/L) 125 (110–194) 110 (88–197) 0.8
Pre-emptive transplant (%) 0 14 (n = 3) 0.08
ESRF (HD/PD) 10 (n = 1) 14 (n = 3) 0.09
Death (% at 5 year follow up) a 30 (n = 3) 14 (n = 3) 0.02
Loss to follow up (%) 30 (n = 3) 10 (n = 2) 0.1
  1. Mann Whitney and Fishers exact test used. Logrank analysis used for ESRF and survival analysis. a Note not median single patient